Schizophrenia, a complex neurological disorder, is comprised of interactions between multiple genetic and environmental factors wherein each of the factors individually exhibits a small effect. In this regard a network-based strategy is best suited to capture the combined effect of multiple genes with their definite pattern of interactions. Given that schizophrenia affects multiple regions of the brain, we postulated that instead of any single specific tissue, a mutual set of interactions occurs between different regions of brain in a well-defined pattern responsible for the disease phenotype. To validate, we constructed and compared tissue specific co-expression networks of schizophrenia candidate genes in twenty diverse brain tissues. As predicted, we observed a common interaction network of certain genes in all the studied brain tissues. We examined fundamental network topologies of the common network to sequester essential common candidates for schizophrenia. We also performed a gene set analysis to identify the essential biological pathways enriched by the common candidates in the network. Finally, the candidate drug targets were prioritized and scored against known available schizophrenic drugs by molecular docking studies. We distinctively identified protein kinases as the top candidates in the network that can serve as probable drug targets for the disease. Conclusively, we propose that a comprehensive study of the connectivity amongst the disease genes themselves may turn out to be more informative to understand schizophrenia disease etiology and the underlying complexity.
Get full access to this article
View all access options for this article.
References
1.
Abi-DarghamA. (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol, 1, S1–S5.
2.
AertsS, LambrechtsD, MaityS, et al. (2006). Gene prioritization through genomic data fusion. Nat Biotechnol, 24, 537–544.
3.
AmbergerJ, BocchiniCA, ScottAF, and HamoshA. (2009). McKusick's Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res, 37, D793–D796.
4.
AndreasenNC, ArndtS, SwayzeV, et al. (1994). Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science, 266, 294–298.
5.
AndreasenNC, EhrhardtJC, SwayzeVW, et al. (1990). Magnetic resonance imaging of the brain in schizophrenia: The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry, 47, 35–44.
6.
AperiaA, and GreengardP. (2006). Dopamine receptor response to NMDA stimulation. Am J Psychiatry, 163, 1682–1682.
7.
AssenovY, RamírezF, SchelhornSE, LengauerT, and AlbrechtM. (2008). Computing topological parameters of biological networks. Bioinformatics, 24, 282–284.
8.
BadrinarayanP, and SastryGN. (2013). Rational approaches towards lead optimization of kinase inhibitors: The issue of specificity. Curr Pharm Des, 19, 4714–4738.
9.
BarabasiAL, and AlbertR. (1999). Emergence of scaling in random networks. Science, 286, 509–512.
10.
BartaPE, PearlsonGD, PowersRE, et al. (1990). Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry, 147, 1457–1462.
11.
Bauer-MehrenA, BundschusM, RautschkaM, MayerMA, SanzF, and FurlongLI. (2011). Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases. PLoS One, 6, e20284.
12.
BergenSE, and PetryshenTL. (2012). Genome-wide association studies of schizophrenia: Does bigger lead to better results?. Curr Opin Psychiatry, 25, 76–82.
13.
BermanHM, WestbrookJ, FengZ, GillilandG, BhatTN, WeissigH, ShindyalovIN, and BournePE. (2000). The Protein Data Bank. Nucleic Acids Res, 28, 235–242.
14.
BindeaG, MlecnikB, HacklH, et al. (2009). ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics, 25, 1091–1093.
15.
BoileauI, PayerD, ChuganiB, et al. (2013). In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: A positron emission tomography study with [11C]-(+)-PHNO. Mol Psychiatry. doi: 10.1038/mp.2013.163. [Epub ahead of print.]
16.
BossiA, and LehnerB. (2009). Tissue specificity and the human protein interaction network. Mol Syst Biol, 5, 260.
17.
BrandesU. (2001). A faster algorithm for betweenness centrality. J Math Sociol, 25, 163–117.
18.
BühlerB, HambrechtM, LöfflerW, an der HeidenW, and HäfnerH. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse: A retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Res, 54, 243–252.
19.
ButteAJ, DzauVJ, and GlueckSB. (2001). Further defining housekeeping, or maintenance, genes Focus on A compendium of gene expression in normal human tissues. Physiol Genomics, 7, 95–96.
20.
CamargoLM, ColluraV, RainJC, MizuguchiK, HermjakobH, KerrienS, BonnertTP, WhitingPJ, and BrandonNJ. (2007). Disrupted in Schizophrenia 1 Interactome: Evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry, 12, 74–86.
21.
CarlssonM, and CarlssonA. (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia—Implications for schizophrenia and Parkinson's disease. Trends Neurosci, 13, 272–276.
22.
ChangCW, ChengWC, ChenCR, ShuWY, TsaiML, HuangCL, and HsuIC. (2011). Identification of human housekeeping genes and tissue-selective genes by microarray meta-analysis. PLoS One, 6, e22859.
23.
ChengWC, ChangCW, ChenCR, et al. (2011). Identification of reference genes across physiological states for qRT-PCR through microarray meta-analysis. PLoS ONE, 6, e17347.
24.
CohenP. (2002). Protein kinases—The major drug targets of the twenty-first century?. Nat Rev Drug Discov, 1, 309–315.
25.
CraigJ. (2008). Complex diseases: Research and applications. Nat Educ, 1, 1.
26.
CritchleyHD, EcclesJ, and GarfinkelSN. (2013). Interaction between cognition, emotion, and the autonomic nervous system. Handb Clin Neurol, 117, 59–77.
27.
DezsoZ, NikolskyY, SviridovE, et al. (2008). A comprehensive functional analysis of tissue specificity of human gene expression. BMC Biol, 6, 49.
28.
DiestelR. (2005). Graph Theory. Springer-Verlag, Heidelberg. ISBN 3-540-26182-6.
29.
DingledineR, BorgesK, BowieD, et al. (1999). The glutamate receptor ion channels. Pharmacol Rev, 51, 7–61.
30.
DivacN, ProstranM, JakovcevskiI, and CerovacN. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int, 2014, 656370.
31.
DixonL, HaasG, WeidePJ, SweeneyJ, and FrancesAJ. (1991). Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry, 148, 224–230.
32.
EisenbergE, and LevanonEY. (2013). Human housekeeping genes, revisited. Trends Genet, 29, 569–574.
33.
EvinsAE, GreenAI, KaneJM, and MurrayRM. (2012). The effect of marijuana use on the risk for schizophrenia. J Clin Psychiatry, 73, 1463–1468.
34.
FabiE, FuscoA, ValianteM, and CelliR. (2013). Genetics and epigenetics of schizophrenia. Clin Ter, 164, e319–24.
35.
FreemanLC. (1979). Centrality in social networks: Conceptual clarification. Soc Networks, 1, 215–239.
36.
FriesnerRA, MurphyRB, RepaskyMP, et al. (2006). Extra Precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem, 49, 6177–6196.
37.
GaoC, and WolfME. (2008). Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons. J Neurochem, 106, 2489–2501.
38.
GilmanSR, ChangJ, XuB, BawaTS, GogosJA, KarayiorgouM, and VitkupD. (2012). Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci, 15, 1723–1728.
39.
GuoAY, SunJ, JiaP, and ZhaoZ. (2010). A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol, 4, 10.
40.
Hans-GertB, GerburgK, JohannS, HenrikD, and BernhardB. (2010). The hypothalamus in schizophrenia research: No longer a wallflower existence. Open Neuroendocrinol J, 3, 59–67.
41.
HarrisonPJ, PritchettD, StumpenhorstK, et al. (2012). Genetic mouse models relevant to schizophrenia: Taking stock and looking forward. Neuropharmacology, 62, 1164–1167.
42.
HowesOD, and KapurS. (2009). The dopamine hypothesis of schizophrenia: Version III—The final common pathway. Schizophr Bull, 35, 549–562.
43.
HsuPC, YangUC, ShihKH, LiuCM, LiuYL, and HwuHG. (2008). A protein interaction based model for schizophrenia study. BMC Bioinformatics, 9, S23.
44.
HuangCH, DengW, ChenZF, et al. (2009). Brain structure abnormality as genetic endophenotype of schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 26, 490–494.
45.
JacobsD, and SilverstoneT. (1986). Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med, 16, 323–329.
46.
JanssensAC, and van DuijnCM. (2008). Genome-based prediction of common diseases: Advances and prospects. Hum Mol Genet, 17, R166–173.
47.
JeongH, MasonSP, BarabasiAL, and OltvaiZN. (2001). Lethality and centrality in protein networks. Nature, 411, 41–42.
48.
JiaP, KaoCF, KuoPH, and ZhaoZ. (2011). A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Syst Biol, 23, S12.
49.
JiaP, SunJ, GuoA, and ZhaoZ. (2010). SZGR: A comprehensive schizophrenia gene resource. Mol Psychiatry, 15, 453–462.
50.
JiaP, WangL, FanousAH, PatoCN, EdwardsTL; International Schizophrenia Consortium, and ZhaoZ. (2012). Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol, 8, e1002587.
51.
JiangT, ZhouY, LiuB, LiuY, and SongM. (2013). Brainnetome-wide association studies in schizophrenia: The advances and future. Neurosci Biobehav Rev, 37, 2818–2835.
52.
KanehisaM, GotoS, SatoY, FurumichiM, and TanabeM. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res, 40, D109–114.
53.
KlompA, KoolschijnPC, Hulshoff PolHE, KahnRS, and HarenNE. (2012). Hypothalamus and pituitary volume in schizophrenia: a structural MRI study. Int J Neuropsychopharmacol, 15, 281–288.
54.
KnoxC, LawV, JewisonT, et al. (2011). DrugBank 3.0: A comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res, 39, D1035–1041.
55.
KumarasingheN, TooneyPA, and SchallU. (2012). Finding the needle in the haystack: A review of microarray gene expression research into schizophrenia. Aust N Z J Psychiatry, 46, 598–610.
56.
LauCI, WangHC, HsuJL, and LiuME. (2013). Does the dopamine hypothesis explain schizophrenia?. Rev Neurosci, 24, 389–400.
57.
LeeSA, TsaoTT, YangKC, et al. (2011). Construction and analysis of the protein-protein interaction networks for schizophrenia, bipolar disorder, and major depression. BMC Bioinformatics, 12, S20.
58.
LuoX, HuangL, JiaP, LiM, SuB, ZhaoZ, and GanL. (2014). Protein-protein interaction and pathway analyses of top schizophrenia genes reveal schizophrenia susceptibility genes converge on common molecular networks and enrichment of nucleosome (chromatin) assembly genes in schizophrenia susceptibility loci. Schizophr Bull, 40, 39–49.
59.
McGuireJL, HammondJH, YatesSD, ChenD, HaroutunianV, Meador-WoodruffJH, and McCullumsmithRE. (2014). Altered serine/threonine kinase activity in schizophrenia. Brain Res, 1568, 42–54.
60.
MorganAA, DudleyJT, DeshpandeT, and ButteAJ. (2010). Dynamism in gene expression across multiple studies. Physiol Genomics, 40, 128–140.
61.
MurrayRM, PaparelliA, MorrisonPD, MarconiA, and Di FortiM. (2013). What can we learn about schizophrenia from studying the human model, drug-induced psychosis?. Am J Med Genet B Neuropsychiatr Genet, 162B, 661–670.
62.
Pelayo-TeránJM, Suárez-PinillaP, ChadiN, and Crespo-FacorroB. (2012). Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des, 18, 5024–5035.
63.
PodderA, JatanaN, and LathaN. (2014). Human Dopamine Receptors Interaction Network (DRIN): A systems biology perspective on topology, stability and functionality of the network. J Theor Biol, 357, 169–183.
64.
PotkinSG, MacciardiF, GuffantiG, et al. (2010). Identifying gene regulatory networks in schizophrenia. Neuroimage, 53, 839–847.
65.
PremkumarP, KumariV, CorrPJ, and SharmaT. (2006). Frontal lobe volumes in schizophrenia: Effects of stage and duration of illness. J Psychiatr Res, 40, 627–637.
66.
PutnamDK, SunJ, and ZhaoZ. (2011). Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling. AMIA Annu Symp Proc, 2011, 1127–1133.
67.
RabinRA, ZakzanisKK, DaskalakisZJ, and GeorgeTP. (2013). Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Res, 206, 158–165.
68.
RastelliG, Del RioA, DegliespostiG, and SgobbaM. (2010). Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem, 31, 797–810.
69.
RivalsI, PersonnazL, TaingL, and PotierMC. (2007). Enrichment or depletion of a GO category within a class of genes: Which test?. Bioinformatics, 23, 401–407.
70.
SchultzSH, NorthSW, and ShieldsCG. (2007). Schizophrenia: A review. Am Fam Physician, 75, 1821–1829.
71.
SchwabSG, and WildenauerDB. (2013). Genetics of psychiatric disorders in the GWAS era: An update on schizophrenia. Eur Arch Psychiatry Clin Neurosci, 2, S147–154.
72.
SebatJ, LevyDL, and McCarthySE. (2009). Rare structural variants in schizophrenia: One disorder, multiple mutations; one mutation, multiple disorders. Trends Genet, 25, 528–535.
73.
SeemanP. (2013). Are dopamine D2 receptors out of control in psychosis?. Prog Neuropsychopharmacol Biol Psychiatry, 4, 146–152.
74.
ShannonP, MarkielA, OzierO, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
75.
SinghS, KumarA, AgarwalS, PhadkeSR, and JaiswalY. (2014). Genetic insight of schizophrenia: Past and future perspectives. Gene, 535, 97–100.
76.
SreedeviC, and DanailGB. (2012). A network view on schizophrenia related genes. Network Biol, 2, 16–25.
77.
SuAI, WiltshireT, BatalovS, et al. (2004). A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci, 101, 6062–6067.
78.
SunJ, JiaP, FanousAH, et al. (2010). Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS One, 5, e11351.
79.
SunJ, JiaP, FanousAH, et al. (2009). A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases–schizophrenia as a case. Bioinformatics, 25, 2595–2602.
80.
SunJ, XuH, and ZhaoZ. (2012). Network-assisted investigation of antipsychotic drugs and their targets. Chem Biodivers, 9, 900–910.
81.
SundayAA. (2011). Can the action of amphetamine on dopamine cause schizophrenia?. Psychol Edu J. Vol. 39, No. 1.
82.
TogninS, RambaldelliG, PerliniC, et al. (2012). Enlarged hypothalamic volumes in schizophrenia. Psychiatry Res, 204, 75–81.
83.
TorkamaniA, BrianD, NicholasJS, and ElizabethAT. (2010). Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res, 20, 403–412.
84.
TsengKY, LewisBL, LipskaBK, and O'DonnellP. (2007). Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. Biol Psychiatry, 62, 730–738.
85.
TuPC, LeeYC, ChenYS, LiCT, and SuTP. (2013). Schizophrenia and the brain's control network: Aberrant within- and between-network connectivity of the frontoparietal network in schizophrenia. Schizophr Res, 147, 339–347.
86.
Van OsJ, RuttenBP, and PoultonR. (2008). Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull, 34, 1066–1082.
87.
VasaikarSV, PadhiAK, JayaramB, and GomesJ. (2013). NeuroDNet—An open source platform for constructing and analyzing neurodegenerative disease networks. BMC Neurosci, 14, 3.
88.
VázquezA, DobrinR, SergiD, EckmannJP, OltvaiZN, and BarabásiAL. (2004). The topological relationship between the large-scale attributes and local interaction patterns of complex networks. Proc Natl Acad Sci USA, 101, 17940–17945.
89.
WernerFM, and CoveñasR. (2014). Safety of antipsychotic drugs: Focus on therapeutic and adverse effects. Expert Opin Drug Saf, 13, 1031–1042.
90.
WernerS, MalaspinaD, and RabinowitzJ. (2007). Socioeconomic status at birth is associated with risk of schizophrenia: Population-based multilevel study. Schizophr Bull, 33, 1373–1378.
91.
WoodruffPW, McManusIC, and DavidAS. (1995). Meta-analysis of corpus callosum size in schizophrenia. J Neurol Neurosurg Psychiatry, 58, 457–461.
92.
YildizM, BorgwardtSJ, and BergerGE. (2011). Parietal lobes in schizophrenia: Do they matter?. Schizophr Res Treatment, 2011, 581686.
93.
YuH, BiW, LiuC, ZhaoY, ZhangJF2, ZhangD, and YueW. (2014). Protein-interaction-network-based analysis for genome-wide association analysis of schizophrenia in Han Chinese population. J Psychiatr Res, 50, 73–78.
94.
ZhouSY, SuzukiM, TakahashiT, et al. (2007). Parietal lobe volume deficits in schizophrenia spectrum disorders. Schizophrenia Res, 89, 35–48.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
